Innovation
The next era of HIV Innovation
We think about HIV everyday so people like Warren don't have to
Scroll to explore
How our R&D approach helps us get
Ahead Together
There’s never been a time when science and technology have formed such a powerful union as they do now. We’re able to identify drug discovery targets using genomics and AI/ML in a way that is unprecedented. We’re also able to use more approaches than ever before to design new vaccines and medicines to address the root cause of disease.
Tony Wood
We’re combining the power of genetic and genomic insights into what causes disease, with the speed and scale of artificial intelligence and machine learning (AI/ML) to make better predictions about who a treatment might work for, and why.
We believe this powerful combination of data and technology holds the key to fundamentally transforming medical discovery for the better, improving R&D success rates and shaping how even the most challenging diseases, like neurological conditions and cancer, can be both prevented and treated.
-
Our R&D investment in 2022
£5.5bn -
An outstanding R&D team of
15k
Ahead of Disease Together
Innovation is at the heart of achieving our purpose: to unite science, technology and talent to get ahead of disease together.
Our pipeline
As a global biopharma leader, we invest heavily in our industry-leading pipeline of potential vaccines and specialty medicines that help us to get ahead of disease together.
Therapeutic areas
The four areas of human health we focus on to get ahead of disease are: infectious diseases, HIV, immunology/respiratory, and oncology. We remain open to opportunities outside these core areas where the science aligns with our strategic approach.
Innovation events and conferences
Hear from industry experts, explore the latest breakthroughs and network with us.
